文献速递炎症性肠病

粪便钙卫蛋白浓度评估溃疡性结肠炎患者治疗结局的诊断准确性

Diagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-08-13

该研究为MOMENTUM试验的事后分析,评估粪便钙卫蛋白(FC)识别溃疡性结肠炎(UC)患者组织学炎症及治疗结局的准确性。第8周(n=639)和第52周(n=373)数据表明,FC可区分内镜下愈合患者中持续显微镜下炎症与组织学缓解,最佳截断值为75-100 μg/g。

要点

  • FC识别组织学缓解的曲线下面积第8周为0.76、第52周为0.80,最佳截断值分别为75 μg/g和99 μg/g。
  • 内镜评分为0的患者中,FC可区分组织学缓解与显微镜下炎症(第8周AUC 0.72,第52周AUC 0.71)。
  • 第52周组织学缓解的预测模型包括第8周内镜评分、第8周FC浓度及基线和第8周组织学活动度。

核心结论

  • 即使UC患者达到完全内镜下愈合,FC浓度仍可区分持续显微镜下炎症与组织学缓解,最佳截断值为75-100 μg/g。

研究设计与样本

  • 对MOMENTUM试验(多基质美沙拉秦治疗轻中度UC的4期试验)数据进行事后分析,获取第8周(n=639)和第52周(n=373)的临床、内镜和组织学数据。

主要发现

  • 达到临床缓解、内镜下愈合、深度缓解或组织学缓解的患者中位FC浓度低于未达到者。
  • FC识别内镜下愈合和组织学缓解的AUC第8周分别为0.77和0.76,第52周分别为0.79和0.80。
  • 识别组织学缓解的最佳FC截断值第8周为75 μg/g,第52周为99 μg/g。
  • 内镜评分为0的亚组中,组织学缓解患者的中位FC浓度低于显微镜下炎症患者:第8周30 vs 140 μg/g(AUC 0.72),第52周21.5 vs 134.5 μg/g(AUC 0.71),两个时间点最佳截断值均约为75 μg/g。
  • 第52周组织学缓解的最终预测模型包括第8周内镜评分、第8周FC浓度以及基线和第8周组织学活动度。

关键数值与推荐

  • FC识别组织学缓解的最佳截断值:第8周75 μg/g,第52周99 μg/g。
  • 内镜评分为0亚组中,两个时间点最佳FC截断值均约为75 μg/g。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Histologic features of inflammation (histologic inflammation) are associated with clinical relapse in patients with ulcerative colitis (UC). Concentration of fecal calprotectin (FC) can be used to identify patients with mucosal inflammation. We aimed to assess the accuracy of FC measurements in identifying patients with histologic inflammation and to develop a model to predict outcomes of therapy. METHODS: We performed a post hoc analysis of data from a phase 4 trial of the efficacy of multimatrix mesalamine in patients with mild to moderate UC (the MOMENTUM trial). We obtained clinical, endoscopic, and histologic data from week 8 (n = 639) and week 52 (n = 373) of the trial. We used area under the receiver operating characteristic curves to determine the accuracy and optimal cut-off values of FC in identifying patients with different therapeutic outcomes (clinical remission, endoscopic healing, deep remission, or histologic remission) at week 8 and week 52. We performed multivariable logistic regression analyses to identify factors associated with these outcomes. RESULTS: Median FC concentrations were lower in patients who achieved outcomes of clinical remission, endoscopic healing, deep remission, or histologic remission vs patients who did not. FC concentrations identified patients with endoscopic healing and histologic remission with area under the receiver operating characteristic curve values of 0.77 and 0.76 at week 8, and 0.79 and 0.80 at week 52, respectively. The optimal FC cut-off concentrations for identification of patients with histologic remission were 75 μg/g at week 8 and 99 μg/g at week 52. In the subpopulation with an endoscopy score of 0, median FC concentrations were lower in patients with histologic remission than in patients with microscopic inflammation at week 8 (30 vs 140 μg/g; area under the receiver operating characteristic, 0.72) and week 52 (21.5 vs 134.5 μg/g; area under the receiver operating characteristic, 0.71). At both time points, the optimal FC cut-off concentration was approximately 75 μg/g. Our final prediction model for week 52 histologic remission comprised endoscopic score at week 8, FC concentration at week 8, and histologic activity at baseline and week 8. CONCLUSIONS: A post hoc analysis of data from a phase 4 trial found that, even in patients with complete endoscopic healing of UC, FC concentration can be used to discriminate patients with ongoing microscopic inflammation from patients with histologic remission. The optimal cut-off concentration of FC is between 75 and 100 μg/g. ClinicalTrials.gov no: NCT01124149.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Stevens TW, Gecse K, Turner JR, et al. Diagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020. PMID: 32801008. doi:10.1016/j.cgh.2020.08.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。